NCT01183715 - A Single Dose Study Of PF-05161704 In Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

PF-05161704 or placebo

PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension

DRUG

PF-05161704 or placebo

PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension

Trial Locations (1)

06511

Pfizer Investigational Site, New Haven